- Home
- Publications
- Publication Search
- Publication Details
Title
Developing TRAIL/TRAIL death receptor-based cancer therapies
Authors
Keywords
TRAIL, Apoptosis, Resistance, Cancer therapy
Journal
CANCER AND METASTASIS REVIEWS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-03-15
DOI
10.1007/s10555-018-9728-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Dopamine Receptors in the Anticancer Activity of ONC201
- (2018) Christina Leah B. Kline et al. NEOPLASIA
- The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
- (2017) Torsten Hartwig et al. MOLECULAR CELL
- ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells
- (2017) Xun Yuan et al. Oncotarget
- A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
- (2017) Isabel Arrillaga-Romany et al. Oncotarget
- Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
- (2017) J. Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of TRAIL-DR5 pathway promotes sensorineural degeneration in the inner ear
- (2016) Shyan-Yuan Kao et al. AGING CELL
- TRAIL deficiency and PP2A activation with salmeterol ameliorates egg allergen-driven eosinophilic esophagitis
- (2016) Leon A. Sokulsky et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
- (2016) T. Ciuleanu et al. ANNALS OF ONCOLOGY
- Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme
- (2016) Filiz Senbabaoglu et al. CANCER BIOLOGY & THERAPY
- Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition
- (2016) Weilong Yao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cleavage by Caspase 8 and Mitochondrial Membrane Association Activate the BH3-only Protein Bid during TRAIL-induced Apoptosis
- (2016) Kai Huang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TRAIL-Induced Caspase Activation Is a Prerequisite for Activation of the Endoplasmic Reticulum Stress-Induced Signal Transduction Pathways
- (2016) Dae-Hee Lee et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Macrophage-epithelial paracrine crosstalk inhibits lung edema clearance during influenza infection
- (2016) Christin Peteranderl et al. JOURNAL OF CLINICAL INVESTIGATION
- Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
- (2016) Jie Yang et al. MOLECULAR CANCER THERAPEUTICS
- Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer
- (2016) Yuting Liu et al. PHARMACOLOGICAL RESEARCH
- ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
- (2016) C. Leah B. Kline et al. Science Signaling
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation
- (2016) Lei Chen et al. Cell Death & Disease
- Discovery and clinical introduction of first-in-class imipridone ONC201
- (2016) Joshua E. Allen et al. Oncotarget
- ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
- (2016) C. Leah B. Kline et al. Science Signaling
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL
- (2016) Margherita Iaboni et al. Molecular Therapy-Nucleic Acids
- Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy
- (2015) Minghua Yang et al. Autophagy
- ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer
- (2015) Jie Yang et al. CANCER BIOLOGY & THERAPY
- Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
- (2015) Kyriakos P. Papadopoulos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner
- (2015) V. V. Prabhu et al. CANCER RESEARCH
- HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
- (2015) Dae-Hee Lee et al. CELLULAR SIGNALLING
- TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
- (2015) A. Forero-Torres et al. CLINICAL CANCER RESEARCH
- Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL
- (2015) Paloma S. Souza et al. EXPERIMENTAL CELL RESEARCH
- Molecular mechanism of ER stress-induced gene expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in macrophages
- (2015) Yan Huang et al. FEBS Journal
- Cell death induced by endoplasmic reticulum stress
- (2015) Raffaella Iurlaro et al. FEBS Journal
- Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer
- (2015) Gopeshwar Narayan et al. GENES CHROMOSOMES & CANCER
- Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
- (2015) Marika Ciprotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
- (2015) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival
- (2015) Laiqun Zhang et al. MOLECULAR AND CELLULAR BIOLOGY
- Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL
- (2015) Rhiannon French et al. Molecular Cancer
- The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway
- (2015) Sung-Chul Lim et al. TUMOR BIOLOGY
- Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5
- (2015) A Fassl et al. Cell Death & Disease
- Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
- (2015) Chan Yoon Cheah et al. Lancet Haematology
- The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling
- (2015) Jing Xu et al. CELL CYCLE
- A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
- (2014) Chuanying Geng et al. AMERICAN JOURNAL OF HEMATOLOGY
- Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Regulates Hallmark Features of Airways Remodeling in Allergic Airways Disease
- (2014) Adam Collison et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells
- (2014) Seog-Young Kim et al. APOPTOSIS
- Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway
- (2014) Iva Jelínková et al. BIOCHEMICAL PHARMACOLOGY
- Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3
- (2014) Gunjal Garg et al. BMC CANCER
- Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. Clinical Lung Cancer
- The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis
- (2014) Gustav J. Ullenhag et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)
- (2014) Mohammad Arabpour et al. JOURNAL OF GENE MEDICINE
- Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma
- (2014) Giulia Pasello et al. Journal of Thoracic Oncology
- Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth
- (2014) Changyou Li et al. Molecular Oncology
- Characterization of the Role of Tumor Necrosis Factor Apoptosis Inducing Ligand (TRAIL) in Spermatogenesis through the Evaluation of Trail Gene-Deficient Mice
- (2014) Yi-Chen Lin et al. PLoS One
- Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype
- (2014) G Cantarella et al. Cell Death & Disease
- Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway
- (2014) R Trivedi et al. Cell Death & Disease
- Tumor necrosis factor–related apoptosis-inducing ligand promotes microvascular endothelial cell hyperpermeability through phosphatidylinositol 3-kinase pathway
- (2013) Hayden W. Stagg et al. AMERICAN JOURNAL OF SURGERY
- A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†
- (2013) A. L. Cohn et al. ANNALS OF ONCOLOGY
- P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway
- (2013) Hanan Galski et al. BIOCHEMICAL PHARMACOLOGY
- TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer
- (2013) Charles S. Fuchs et al. CANCER
- Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential
- (2013) Kei Takahashi et al. CANCER SCIENCE
- Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
- (2013) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Human Cytomegalovirus Glycoprotein UL141 Targets the TRAIL Death Receptors to Thwart Host Innate Antiviral Defenses
- (2013) Wendell Smith et al. Cell Host & Microbe
- C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1-Dependent Pathway
- (2013) P. Secchiero et al. CLINICAL CANCER RESEARCH
- A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
- (2013) Zev A. Wainberg et al. Clinical Colorectal Cancer
- Regulation of the Src-PP2A Interaction in Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis
- (2013) Jing Xu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Azadirone, a Limonoid Tetranortriterpene, Induces Death Receptors and Sensitizes Human Cancer Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) through a p53 Protein-independent Mechanism
- (2013) Subash C. Gupta et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2013) Luis Paz-Ares et al. Journal of Thoracic Oncology
- A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
- (2013) Martin Reck et al. LUNG CANCER
- APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc Receptors
- (2013) C. Gieffers et al. MOLECULAR CANCER THERAPEUTICS
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis
- (2013) S-A Quast et al. Cell Death & Disease
- TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma
- (2013) M Keuper et al. Cell Death & Disease
- Dengue Virus Activates Membrane TRAIL Relocalization and IFN-α Production by Human Plasmacytoid Dendritic Cells In Vitro and In Vivo
- (2013) Mariana Gandini et al. PLoS Neglected Tropical Diseases
- Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
- (2013) Andres Forero-Torres et al. Cancer Medicine
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis
- (2012) Syam Prakash Somasekharan et al. APOPTOSIS
- Amurensin G, a novel SIRT1 inhibitor, sensitizes TRAIL-resistant human leukemic K562 cells to TRAIL-induced apoptosis
- (2012) Hak-Bong Kim et al. BIOCHEMICAL PHARMACOLOGY
- Regulation of the human TRAIL gene
- (2012) Joshua E. Allen et al. CANCER BIOLOGY & THERAPY
- Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors
- (2012) Hairong Cheng et al. CELL CYCLE
- Glucose—a sweet way to die
- (2012) Marion MacFarlane et al. CELL CYCLE
- Control of FLIPL expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells
- (2012) R Yerbes et al. CELL DEATH AND DIFFERENTIATION
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
- (2012) George D. Demetri et al. EUROPEAN JOURNAL OF CANCER
- TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells
- (2012) Ling Xu et al. EUROPEAN JOURNAL OF CANCER
- Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS–JNK–CHOP-mediated upregulation of death receptors
- (2012) Bokyung Sung et al. FREE RADICAL BIOLOGY AND MEDICINE
- Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA
- (2012) Marie P. Piechocki et al. INTERNATIONAL JOURNAL OF CANCER
- Smad7 Protein Induces Interferon Regulatory Factor 1-dependent Transcriptional Activation of Caspase 8 to Restore Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Apoptosis
- (2012) Suntaek Hong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Protein-induced Lysosomal Translocation of Proapoptotic Effectors Is Mediated by Phosphofurin Acidic Cluster Sorting Protein-2 (PACS-2)
- (2012) Nathan W. Werneburg et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension
- (2012) Abdul G. Hameed et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions
- (2012) Hongqin Zhuang et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- PKC Regulates Death Receptor 5 Expression Induced by PS-341 through ATF4-ATF3/CHOP Axis in Human Lung Cancer Cells
- (2012) L. Xu et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the Glyoxalase Pathway Enhances TRAIL Efficacy in Cancer Cells by Downregulating the Expression of Antiapoptotic Molecules
- (2012) H. Taniguchi et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
- (2012) V. Subbiah et al. MOLECULAR CANCER THERAPEUTICS
- TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo
- (2012) Benny Perlstein et al. NEURO-ONCOLOGY
- TRAF-6 Dependent Signaling Pathway Is Essential for TNF-Related Apoptosis-Inducing Ligand (TRAIL) Induces Osteoclast Differentiation
- (2012) Men-Luh Yen et al. PLoS One
- MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation
- (2012) G. Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL
- (2012) M Grunert et al. Cell Death & Disease
- Zyflamend Sensitizes Tumor Cells to TRAIL-Induced Apoptosis Through Up-Regulation of Death Receptors and Down-Regulation of Survival Proteins: Role of ROS-Dependent CCAAT/Enhancer-Binding Protein-Homologous Protein Pathway
- (2011) Ji Hye Kim et al. ANTIOXIDANTS & REDOX SIGNALING
- Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
- (2011) Y Pan et al. BRITISH JOURNAL OF CANCER
- Cisplatin Restores TRAIL Apoptotic Pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP
- (2011) Lijuan Ding et al. CANCER INVESTIGATION
- Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer
- (2011) D. Malin et al. CLINICAL CANCER RESEARCH
- Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity
- (2011) Shen Gao et al. International Journal of Nanomedicine
- Wogonin and Related Natural Flavones Overcome Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Protein Resistance of Tumors by Down-regulation of c-FLIP Protein and Up-regulation of TRAIL Receptor 2 Expression
- (2011) Jie Ding et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Importin β1 Protein-mediated Nuclear Localization of Death Receptor 5 (DR5) Limits DR5/Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Cell Death of Human Tumor Cells
- (2011) Yuko Kojima et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Oligomycin A enhances apoptotic effect of TRAIL through CHOP-mediated death receptor 5 expression
- (2011) Long He et al. MOLECULAR CARCINOGENESIS
- Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells
- (2010) Eun-Sil Sung et al. APOPTOSIS
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death
- (2010) Kageaki Kuribayashi et al. CANCER BIOLOGY & THERAPY
- Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
- (2010) Andres Forero-Torres et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
- (2010) T. Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- A Genetically Encoded Multifunctional TRAIL Trimer Facilitates Cell-Specific Targeting and Tumor Cell Killing
- (2010) D. Spitzer et al. MOLECULAR CANCER THERAPEUTICS
- Activation of the Akt Survival Pathway Contributes to TRAIL Resistance in Cancer Cells
- (2010) Jing Xu et al. PLoS One
- TRAIL as a target in anti-cancer therapy
- (2009) Gen Sheng Wu CANCER LETTERS
- Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells
- (2009) Takeshi Hori et al. CANCER LETTERS
- Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling
- (2009) Zhaoyu Jin et al. CELL
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
- (2009) C. H. Mom et al. CLINICAL CANCER RESEARCH
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- (2009) Stephen Leong et al. JOURNAL OF CLINICAL ONCOLOGY
- Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
- (2009) T. A. Luster et al. MOLECULAR CANCER THERAPEUTICS
- Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions
- (2009) Patrizia Marini et al. Radiation Oncology
- TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
- (2008) Monzur Rahman et al. BREAST CANCER RESEARCH AND TREATMENT
- Sp1-Mediated TRAIL Induction in Chemosensitization
- (2008) J. Xu et al. CANCER RESEARCH
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
- (2008) S. J. Hotte et al. CLINICAL CANCER RESEARCH
- Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
- (2008) H. Jin et al. CLINICAL CANCER RESEARCH
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now